Biome to Launch Biome Her™ Pessary and Perinatal Probiotic in Q4 FY25

Expanding the Activated Probiotics Portfolio

Biome Australia Limited (ASX: BIO) has announced the upcoming launch of two new products under its flagship Activated Probiotics brand, aimed squarely at women’s health. Scheduled for release in the fourth quarter of fiscal year 2025, the Biome Her™ Pessary and Biome Perinatal™ Probiotic represent a strategic push into high-demand segments within the complementary medicines market.

Women’s health supplements currently lead the Australian market by sales volume, reflecting a growing consumer focus on targeted, evidence-based natural health solutions. Biome’s new offerings are designed to support women at critical life stages, from managing vaginal microbiome balance to promoting healthy pregnancy outcomes and postpartum mood stability.

Biome Her™ Pessary: Targeted Vaginal Microbiome Support

The Biome Her™ Pessary complements the existing oral Biome Her™ Probiotic by providing a vaginally-inserted probiotic option. This product contains clinically-trialled strains including Lactobacillus acidophilus LA02 and Lactobacillus fermentum LF10, which have demonstrated a significant reduction in relapse rates of recurrent vaginal thrush, from as high as 57% with standard treatment alone down to 27.6% when used adjunctively.

Registered on the Australian Register of Therapeutic Goods, the pessary is intended for short-term use in women experiencing acute vaginal health concerns, offering a practitioner-only option to re-establish and maintain healthy vaginal flora. Given that approximately 70% of women experience vaginal thrush at some point, with 10% suffering recurrent episodes, this product addresses a substantial unmet need.

Biome Perinatal™ Probiotic: Supporting Pregnancy and Beyond

Biome Perinatal™ Probiotic targets women before, during, and after pregnancy, including the breastfeeding period. It features a blend of clinically-supported probiotic strains such as Lactobacillus rhamnosus HN001, known for reducing gestational diabetes risk, improving postpartum mood, and potentially protecting children against eczema when supplemented early in life.

With nearly 300,000 pregnancies annually in Australia and prenatal multivitamin sales reaching $98.6 million in 2024, Biome Perinatal™ offers a compelling co-prescribing opportunity alongside existing prenatal supplements. The product is also listed on the Australian Register of Therapeutic Goods with claims supporting healthy pregnancy, maternal health, and emotional well-being postpartum.

Market Context and Strategic Implications

The global women’s probiotic market is projected to grow at a robust compound annual growth rate (CAGR) of 18.1% over the next decade, with the Australia and New Zealand region expected to expand at 8.2%. Biome’s focus on practitioner-only distribution channels underscores its commitment to evidence-based natural medicines and professional education, positioning the company to capitalize on rising consumer demand for female-focused health products.

These launches reinforce Biome’s strategy to leverage clinically validated probiotic strains and innovative delivery formats to address prevalent health concerns. By targeting both acute vaginal health issues and the perinatal period, Biome is broadening its reach within a demographic that is both highly engaged and a primary purchaser of complementary medicines.

Looking Ahead

While the announcement does not include explicit financial forecasts, the clinical backing and regulatory approvals provide a strong foundation for market acceptance. Investors and health professionals alike will be watching closely to see how these new products perform in a competitive and rapidly evolving sector.